Human Papillomavirus (HPV): A Complete Overview

1. Virology

Genome Organization

2. HPV Types

• Mucosal (~40 types) vs. cutaneous types
• Low-risk types: HPV 6 and 11 - cause genital warts (condyloma acuminata) and laryngeal/recurrent respiratory papillomatosis
• High-risk (oncogenic) types: HPV 16 and 18 are the most important
  • HPV 16 and 18 cause ~70% of cervical cancers
  • HPV 16 drives ~96% of HPV-positive oropharyngeal cancers
  • Other high-risk types: 31, 33, 45, 52, 58

3. Life Cycle & Pathogenesis

Entry

Replication - Two Phases

1. Maintenance phase: Virus maintains 50-100 episomal copies per basal cell. E1 and E2 proteins sustain low-level replication. Crucially, this low copy number helps the virus evade immune detection.
2. Differentiation-dependent phase: As cells move into the suprabasal layer, E6 and E7 drive continued cell proliferation. Late promoter activation produces thousands of viral copies per cell. L1 and L2 capsid proteins are expressed and new virions are shed during normal epithelial cell shedding (not cell lysis - another immune evasion strategy).

Oncogenesis - The E6/E7 Mechanism

• E7 binds and inactivates pRb (retinoblastoma protein), releasing E2F transcription factors and forcing the cell into uncontrolled S-phase (DNA replication)
• E6 binds and degrades p53, blocking the apoptotic response that would normally follow
• With both tumor suppressors disabled, cells accumulate mutations and chromosomal instability, leading to malignant transformation
• p16 overexpression is a surrogate marker: because E7 disrupts pRb, negative feedback on p16 is lost, causing p16 to accumulate - used diagnostically in pathology

4. Clinical Manifestations

Benign Lesions

• Common warts (verruca vulgaris): HPV 2, 4 - skin
• Plantar warts: HPV 1, 2
• Flat warts: HPV 3, 10
• Genital warts / condyloma acuminata: HPV 6, 11 - soft, flesh-colored exophytic lesions of the genitals, perineum, anus
• Recurrent respiratory papillomatosis (RRP): HPV 6, 11 - laryngeal papillomas, can cause hoarseness and airway obstruction; perinatal transmission from mother to child

Premalignant/Malignant Lesions

• Cervical intraepithelial neoplasia (CIN) - graded I, II, III; CIN III = carcinoma in situ
• Cervical cancer: predominantly HPV 16, 18 - 99% of cases are HPV-positive
• Anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma
• Oropharyngeal squamous cell carcinoma (OPSCC): HPV 16 dominant; as of 2020, HPV-associated head and neck cancers in the US now exceed cervical cancer in incidence
• Penile, vulvar, and vaginal cancers: less common but HPV-associated
• Epidermodysplasia verruciformis (EV): rare, with HPV-5 and -8 causing SCCs on sun-exposed skin; acquired form (AEDV) seen in HIV patients

HPV in Immunocompromised Patients

• Higher HPV prevalence and reduced clearance
• 3x increased incidence of CIN and higher-grade lesions

• 90% anal HPV prevalence in MSM with HIV; up to 50% prevalence of high-grade AIN

• 30-50x higher anal cancer risk; 5x higher penile cancer risk compared to the general population

5. Screening

Cervical Cancer Screening (USPSTF Guidelines)

• HPV DNA testing alone as primary cervical screening is an evolving area; it is not universally adopted as a standalone primary screen in all settings
• Colposcopy with biopsy is indicated for abnormal Pap (e.g., ASC-US with positive HPV, LSIL, HSIL) - allows directed biopsies of acetowhite lesions
• During pregnancy: cytology, HPV testing, and physical exam are used; endocervical curettage is avoided

Anal Cancer Screening

• No universal guidelines from USPSTF
• International Anal Neoplasia Society consensus recommends screening in high-risk groups (HIV-positive, MSM, immunocompromised)
• Methods: anal cytology, high-resolution anoscopy (HRA)

Oropharyngeal Cancer

• No established screening guidelines as of now
• HPV vaccination expected to reduce incidence over time

6. Vaccines

Vaccination Schedule (ACIP Recommendations)

• Routine: Age 11-12 years (can start at age 9); 2-dose series if started before age 15 (0 and 6-12 months)
• Catch-up: Through age 26 for all unvaccinated males and females; 3-dose series if starting at ≥15 years
• Ages 27-45: Shared clinical decision-making (not routine recommendation); benefit decreases with prior exposure
• Not licensed for adults over 45

• Vaccines are prophylactic only - they prevent new HPV infections but do NOT treat established infection or reverse HPV-related disease
• Protection lasts >10 years (ongoing studies suggest likely longer)
• Herd immunity effect: reduces HPV prevalence even in unvaccinated individuals
• Effective in HIV-positive patients, though antibody titers are somewhat lower (recommend 3-dose series in PLWH); vaccination recommended up to age 26 in PLWH

7. Treatment of HPV-Related Lesions

Genital Warts

• Imiquimod and podophyllotoxin should NOT be used for vaginal, cervical, or anal lesions
• Safety in pregnancy not established for imiquimod

Cervical Disease

• CIN I: often observed (high spontaneous regression rate)
• CIN II/III: ablative or excisional therapy (LEEP - loop electrosurgical excision procedure, cold knife cone biopsy, cryotherapy)
• Invasive cervical cancer: surgery (hysterectomy), radiation, chemotherapy depending on stage

Human Papillomavirus (HPV) - Illustrated Overview

1. Virology - Structure

2. Genome Organization

• LCR - Long control region (enhancer/promoter/origin of replication)
• E6 - Binds and degrades p53; activates telomerase; suppresses apoptosis
• E7 - Binds and inactivates pRb (p105 retinoblastoma protein)
• E1 - Viral DNA replication (helicase activity)
• E2 - Transcriptional and replication regulator; suppresses E6/E7 in productive infection
• E4 - Disrupts cytokeratins; promotes virion release
• E5 - Activates EGF receptor; promotes cell growth
• L2 - Minor capsid protein
• L1 - Major capsid protein (target of all HPV vaccines) (Medical Microbiology 9e)

3. Life Cycle - Epithelial Layer Replication

• Basal keratinocytes: Initial infection; viral DNA enters nucleus; cell proliferation begins; only a few viral copies maintained (immune evasion)
• Stratum spinosum: Active genome replication as cells differentiate
• Stratum granulosum: Virion maturation - L1 and L2 capsid proteins assembled
• Stratum corneum: Release of thousands of mature virions during normal epithelial shedding (not cell lysis - another immune evasion mechanism) (Medical Microbiology 9e)

4. Oncogenesis - Koilocytes (Hallmark of HPV Infection)

5. Condyloma Acuminatum - Histology

• (A) Low power: Branching villous/papillary architecture with acanthosis (epidermal thickening) and hyperkeratosis - the classic "cauliflower" appearance histologically
• (B) High power: Koilocytosis - perinuclear cytoplasmic vacuolization with shrunken nuclei; this is the defining feature of productive HPV infection in tissue sections (Robbins & Cotran Pathologic Basis of Disease)

6. Bowen Disease (HPV-Associated Carcinoma In Situ)

• Hyperchromatic, dysplastic, dyskeratotic epithelial cells throughout all layers
• Loss of orderly maturation (full-thickness dysplasia)
• Scattered mitoses above the basal layer (abnormal mitotic figures)
• Intact basement membrane (in situ - not yet invasive)

Summary: Key HPV Types at a Glance

The E6/E7 Oncogenic Mechanism (Summary)

HPV integrates → E2 disrupted → E6/E7 unleashed
        ↓                              ↓
   E6 degrades p53           E7 inactivates pRb
        ↓                              ↓
  No apoptosis            Uncontrolled S-phase entry
        ↓                              ↓
  DNA mutations         ──→ Genomic instability ──→ CANCER